BIO-2-HEART: Identification of Biomarkers in T2DM and Heart Failure

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRWTH Aachen University

About this trial

The primary aim of the current study is a better understanding of the role of Type 2 Diabetes Mellitus (T2DM) in heart failure and, in particular, changes in cardiac metabolism, which may contribute to heart failure. Various biomarkers in the coronary artery blood, as well as in the arterial and peripheral venous blood, are to be identified for this purpose. Included are patients with and without T2DM and with or without heart failure (HFpEF, HFmrEF, HFrEF), who have a clinically indicated and guidance-appropriate Cardiac Resynchronisation Therapy (CRT) implantation or pulmonary vein ablation/electrophysiological examination.

Not all patients currently benefit from the implantation of a CRT system (so-called non-responder). Despite narrow inclusion criteria, these "non-responders" cannot be unmasked in advance of the implantation. A further aim of this study is to identify biomarkers, which can be determined in advance of implantation to differentiate between responders and non-responders.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

guideline-appropriate clinical indication for CRT implantation/electrophysiologial examination/pulmonary vein ablation

age of majority

written declaration of consent

persons who are able to work and mentally able to follow the instructions of the study staff

Disqualifiers

anemia Hb <8 mg / dl

patients with acute infectious disease (e.g. pneumonia)

non-intubatable coronary sinus

patients who do not have access to the subclavian vein (e.g. thrombosis of the subclavian vein or superior vena cava)

Trial population

Patients with and without heart failure (HFrEF, HFmrEF, HFpEF) plus known status of type 2 diabetes (yes/no)

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • 6-minute walk test

    Diagnostic test

    The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed. Test is performed prior the intervention and 6 months after the intervention.

  • Study specific questionnaire

    Diagnostic test

    Study specific questionnaire The questionnaire is performed prior and 6 months after the intervention.

  • Blood collection

    Procedure/Surgery

    Blood collection during surgery: * coronary sinus * arterial * peripheral venous Blood collection 6 months after surgery: \- peripheral venous

Treatment groups

400 Participants
are divided into 3 treatment groups
Group A: No diabetes3 interventions
Group B: Type 2 diabetes3 interventions
Group C: Prediabetes3 interventions

Trial outcomes

Primary outcomes

1

Oxygen partial pressure (pO2) [mmHg]

Results of blood gas analysis: Oxygen partial pressure (pO2) \[mmHg\]

Time frame
Directly prior to the CRT-implantation
2

Oxygen partial pressure (pO2) [mmHg]

Results of blood gas analysis: Oxygen partial pressure (pO2) \[mmHg\]

Time frame
6 months after CRT-implantation
3

Carbon dioxide partial pressure (pCO2) [mmHg]

Results of blood gas analysis: Carbon dioxide partial pressure (pCO2) \[mmHg\]

Time frame
Directly prior to the CRT-implantation
4

Carbon dioxide partial pressure (pCO2) [mmHg]

Results of blood gas analysis: Carbon dioxide partial pressure (pCO2) \[mmHg\]

Time frame
6 months after CRT-implantation

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.